Phillips-Medisize Invests in Manufacturing Center of Excellence for Connected Health and Drug-Delivery Devices

News
Article

The company is expanding its 380,000-square-feet Molex Little Rock facility to include a FDA-registered manufacturing center of excellence for connected health and drug-delivery devices.

Phillips-Medisize, a Molex company, announced on Dec. 6, 2017 that it is expanding its 380,000-square-feet Molex Little Rock facility to include a FDA-registered manufacturing center of excellence for connected health and drug-delivery devices. The construction of purpose-built cleanroom suites, as well as FDA registration and ISO 13485 certification are scheduled to be completed for production in the second quarter of 2018.

This facility will serve as the new manufacturing site in Little Rock, Arkansas for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics, and connected devices. It will combine the expertise of Molex’s existing electronics production operations with Phillips-Medisize’s platform of drug delivery and medical device expertise.

“Phillips-Medisize is excited to align with Molex on the transformation of the Little Rock
facility, which will be a center of excellence for connected health and drug-delivery devices and manufacture products that fit in today’s world of innovative devices. This facility will also allow us to accommodate large programs requiring extensive assembly and molding operations, in cleanroom and other controlled environments, within a compressed timeframe. The facility will have a particular focus on mid- to high-volume diagnostics, medical device and drug delivery systems that integrate electronics and digital applications, and will provide us with the additional space needed to reach our growth objectives over the upcoming years,” commented Matt Jennings, CEO and president of Phillips-Medisize in a press statement.

This investment is the company’s sixth expansion in the past six years to support long-term growth of its medical contract manufacturing business. In June 2017, the company completed a new 80,000-square-feet facility in Menomonie, Wisconsin. Earlier in 2016, Phillips-Medisize opened a 17,000-square-feet dedicated clinical and pilot build facility for drug delivery and combination devices in Menomonie, Wisconsin. In November 2015, the company doubled the size of the New Richmond, Wisconsin medical-device facility, and in late 2014, its Finland facility was expanded. These investments demonstrate ongoing support for biopharmaceutical and device customers by providing design, development, and manufacturing solutions for both mechanical and connected devices across multiple geographies.

Source: Phillips-Medisize

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content